<DOC>
	<DOCNO>NCT01200394</DOCNO>
	<brief_summary>PF-00489791 inhibitor phosphodiesterase type 5 . Our hypothesis PF-00489791 enhance relaxation blood vessel within kidney reduce blood pressure , improve renal function .</brief_summary>
	<brief_title>A Phase 2 , Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Male female subject great equal 18 year . Female subject must nonchild bear potential . Clinical diagnosis type 2 diabetes together stage 3a , 3b 4 CKD , base eGFR 2559 mL/min/1.73m2 . Evidence persistent , overt albuminuria ; define UACR great equal 300 mg/g ( great equal 33.9 mg/mmol ) great 3 month . Subjects CKD result type 1 diabetes nondiabetic CKD . Subjects poorly control diabetes mellitus , define HbA1C &gt; 9 % . Subjects combination ACE inhibitor/ARB therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>PF-00489791</keyword>
	<keyword>phosphodiesterase</keyword>
	<keyword>PDE5</keyword>
</DOC>